Sirolimus in liver transplant recipients: A large single-center experience

Transplantation Proceedings

Volumn 42, Issue 7, 2010, Pages 2579-2584

  Vivarelli, M ^a   Dazzi, A ^a   Cucchetti, A ^a   Gasbarrini, A ^b   Zanello, M ^a   Di Gioia, P ^a   Bianchi, G ^a   Tam, M R ^a   Gaudio, M D ^a   Ravaioli, M ^a   Cescon, M ^a   Grazi, G L ^a   Pinna, A D ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; METHYLPREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEG EDEMA; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUROLOGIC DISEASE; NEUROTOXICITY; POSTOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENCE RISK; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; SIROLIMUS; TIME FACTORS;

EID: 77956478746     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.04.045     Document Type: Article

References (23)

1. J. Fung, D. Kelly, and Z. Kadry Immunosuppression in liver transplantation Beyond calcineurin inhibitors Liver Transpl 11 2005 267
2. G.J. Chang, H.D. Mahanty, and D. Quan Experience with the use of sirolimus in liver transplantationuse in patients for whom calcineurine inhibitors are contraindicated Liver Transpl 6 2000 734
3. I. Morard, J. Dumortier, and L. Spahr Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients Liver Transpl 13 2007 658
4. M. Guba, C. Graeb, and K.-W. Jauch Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation Transplantation 77 2004 1777
5. C.J. Watson, P.J. Friend, and N.V. Jamieson Sirolimus: a potent new immunosuppressant for liver transplantation Transplantation 67 1999 4
6. K.D. Fairbanks, J.A. Eustace, and D. Fine Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079
7. N.M. Kneteman, J. Oberholzer, and M. AI Saghier Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma Liver Transpl 10 2004 1301
8. C. Toso, G.A. Meeberg, and D.L. Bigam De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects Transplantation 83 2007 1162
9. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
10. M. Montalbano, G.W. Neff, and N. Yamashiki A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications Transplantation 78 2004 264
11. M.H. Gault, L.L. Longerich, and J.D. Harnett Predicting glomerular function from adjusted serum creatinine Nephron 62 1992 249
12. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis N Eng J Med 334 1996 693
13. H.A. Edmondson, and P.E. Steiner Primary carcinoma of the liver A study of 100 cases among 48,900 necropsies Cancer 7 1954 462
14. T.A. Gonwa, M.L. Mai, and L.B. Melton End-stage renal disease (ESDR) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy Transplantation 72 2001 1934
15. W.O. Bechstein Neurotoxicity of calcineurin inhibitors: impact and clinical management Transpl Int 13 2000 313
16. J.C. Dunkelberg, J.F. Trotter, and M. Wachs Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications Liver Transpl 9 2003 463
17. C.J. Watson, A.E. Gimson, and G.J. Alexander A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function Liver Transpl 13 2007 1694
18. D. DuBay, R.J. Smith, and K.G. Qiu Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 2008 651
19. M. Vivarelli, G. Vetrone, and M. Zanello Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature Transpl Int 19 2006 1022
20. M. Vivarelli, A. Cucchetti, and F. Piscaglia Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression Liver Transpl 11 2005 497
21. J.J. Fung, E.J. Kwak, and S. Kusne De novo malignancies after liver transplantation: a major cause of death Liver Transpl 7 2001 S109
22. A. Reuben Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity Liver Transpl 7 2001 S13
23. G. Bianchi, G. Marchesini, and R. Marzocchi Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression Liver Transpl 14 2008 1648